Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050097 · ClinicalTrials.gov registry record · Phase 1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
- 20
- Study locations
NCT05050097 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 166 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05050097, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Pomalidomide
- DRUG Carfilzomib
- DRUG Talquetamab
- DRUG Daratumumab SC
Study Locations (20)
Other
- St Vincents Hospital Melbourne - Fitzroy
- Alfred Health - Melbourne
- Gold Coast University Hospital - Southport
- Wollongong Hospital - Wollongong
- Cliniques Universitaires St-Luc - Brussels
- UZA - Edegem
- UZ Gent - Ghent
- UZ Leuven - Leuven
New York
- Mt. Sinai School of Medicine - New York
- Weill Cornell Medical College - New York
Alabama
- University of Alabama Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Georgia
- Emory University - Atlanta
Indiana
- Indiana University - Indianapolis
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2027-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050097
The ClinicalTrials.gov registry entry for NCT05050097 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (70% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Lenalidomide is the first listed.
NCT05050097 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT05050097 about?
NCT05050097 is a clinical study titled "A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma". The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
What is the current status of trial NCT05050097?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2021-09-22. Estimated completion is 2027-04-07.
What conditions does trial NCT05050097 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05050097?
The interventions under investigation include: Lenalidomide (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG), Talquetamab (DRUG), Daratumumab SC (DRUG).
Who is sponsoring clinical trial NCT05050097?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05050097 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.